CTI BioPharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2014	FY 2013	FY 2012	FY 2011
Period Ending	Jun '15 Jun 30, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012	Dec '11 Dec 31, 2011
Net Income	-2.45	-2.29	-1.33	-1.78	-0.96
Depreciation & Amortization	0.19	0.13	0.04	0.02	-
Asset Writedown & Restructuring Costs	0.3	-	-	-	0.41
Stock-Based Compensation	0.52	0.6	0.03	0.17	0
Other Operating Activities	0.17	0.16	0.1	1.04	-0.04
Change in Accounts Receivable	0.06	-0	-0.03	-	-
Change in Accounts Payable	0.18	0.26	0.1	-0.04	0.02
Change in Other Net Operating Assets	0.35	0.11	-0.18	0.05	0.03
Operating Cash Flow	-0.69	-1.03	-1.27	-0.52	-0.54
Capital Expenditures	-0.86	-1.14	-0.48	-0.41	-0.36
Cash Acquisitions	-	-	-	-	-0.36
Investing Cash Flow	-0.86	-1.14	-0.48	-0.41	-0.72
Long-Term Debt Issued	-	2.4	0.08	0.03	-
Total Debt Issued	0.49	2.4	0.08	0.03	1.68
Short-Term Debt Repaid	-	-0.07	-0.29	-0.2	-
Total Debt Repaid	-	-0.07	-0.29	-0.2	-0.24
Net Debt Issued (Repaid)	0.49	2.34	-0.22	-0.17	1.44
Issuance of Common Stock	0.06	0.09	2.01	0.67	0.3
Other Financing Activities	-	-	-	-	0.11
Financing Cash Flow	0.55	2.43	1.79	0.5	1.85
Net Cash Flow	-1	0.26	0.04	-0.43	0.59
Free Cash Flow	-1.55	-2.17	-1.75	-0.93	-0.9
Free Cash Flow Margin	-393.83%	-455.44%	-2669.35%	-3100.48%	-
Free Cash Flow Per Share	-0.07	-0.10	-0.09	-0.07	-0.15
Levered Free Cash Flow	-1.02	-1.91	-1.03	-0.04	-
Unlevered Free Cash Flow	-0.83	-1.75	-0.98	0.01	-
Change in Net Working Capital	-0.56	0.04	-0.21	-0.2	-

Updated Sep 2, 2015. Source: S&P Global Market Intelligence. Standard template. Financial Sources.